The oral health status of patients on oral bisphosphonates for osteoporosis

Australian Dental Journal

Volumn 53, Issue 4, 2008, Pages 354-357

  Kunchur, R ^a   Goss, A N ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Bisphosphonates; DMFT; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ARTICLE; BONE NECROSIS; FEMALE; HEALTH; HEALTH STATUS; HEALTH SURVEY; HUMAN; JAW DISEASE; MALE; MIDDLE AGED; NEEDS ASSESSMENT; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PERIODONTAL DISEASE; RETROSPECTIVE STUDY; RISK ASSESSMENT; TOOTH EXTRACTION;

ADMINISTRATION, ORAL; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DMF INDEX; FEMALE; HEALTH STATUS; HUMANS; JAW DISEASES; MALE; MIDDLE AGED; NEEDS ASSESSMENT; ORAL HEALTH; OSTEONECROSIS; OSTEOPOROSIS; PERIODONTAL DISEASES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TOOTH EXTRACTION;

EID: 63849102923     PISSN: 00450421     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1834-7819.2008.00078.x     Document Type: Article

References (14)

1. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003;61:1104-1107.
2. Marx RE. Pamidronate (Aredia) and zoledronate (ZometaS induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1117.
3. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003;21:4253-4254.
4. Carter G, Goss AN. Bisphosphonates and avascular necrosis of the jaws. (Letter to the Editor.) Aust Dent J 2003;48:268.
5. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534.
6. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 2005;63:1567-1575.
7. Cheng A, Mavrokokki A, Carter G, et al. The dental implications of bisphosphonates and bone disease. Aust Dent J 2005;50(Suppl 2):S4-S13.
8. Hoff AO, Toth BB, Altundag K, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 2006;24:8528-8534.
9. Mavrokokki A, Cheng A, Stein B, Goss AN. The nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-423.
10. Sambrook P, Olver I, Goss AN. Bisphosphonates and osteonecrosis of the jaw. Position statement on behalf of the Australian and New Zealand Bone Mineral Society, Osteoporosis Australia, Medical Oncology Group of Australia and the Australian Dental Society. Aust Fam Physician 2006;35:801-803.
11. Kunchur R, Need A, Hughes T, Goss AN. A clinical investigation of the CTX test in the prevention and management of bisphosphonate associated ONJ. J Oral Maxillofac Surg 2008 (in press).
12. Oral Health - DMFT. World Health Organization Global Infobase. Available from: http://www.who.int/infobase/report viewer.aspx?rptcode=ALL&surveycode= 160021b4&dm=6pgstringl. Accessed 9 January 2008.
13. Seymour RA, Preshaw PM, Steele JG. Oral health and heart disease. Prim Dent Care 2002;9:125-131.
14. Therapeutic Guidelines. Oral and Dental. Version 1. Melbourne: Therapeutic Guidelines Ltd, 2007:75-79.